The inflammatory bowel disease (IBD) pipeline of Shanghai Lishan Biopharmaceutical Co., Ltd. has completed all the preparations for the preliminary FDA application and will undergo IND application in November this year, fully opening a new chapter of commercialization.   On the afternoon of September 25, 2024, the IBD pipeline commercialization progress report meeting of Lishan Biotech Zhangjiang Live Biopharmaceutical (LBP) R&D Center was held at Zhangjiang Pharmaceutical Valley. Professor Su Bing, Chief Scientist of Lishan Biotech and Director of Shanghai Institute of Immunology, and Professor Ma Jianpeng, Senior Advisor of Lishan Biotech and Dean of the Institute of Complex Systems Multiscale Research at Fudan University, accompanied by Mr. Long Kejin, Supervisor of Lishan Biotech, and Dr. Zhu Chaoyu, Dire...

Dr. Chen Weijie Chairman of Lishan Biotechnology Hello Dr. Li Changqing, I am very pleased today and welcome you to Lishan. Today we will have a brief interview to discuss your views as a former FDA senior medical reviewer on clinical trials of live bacteria drugs. Can you describe the uniqueness of clinical trials for live bacteria drugs and how they differ from other small molecule drugs? Thank you for choosing to collaborate deeply with Lishan Biotech. We also hope that you can introduce the precautions that need to be taken in multi center clinical trials.   Dr. Li Changqing Eglin Medical Clinical Expert Thank you, the topic you mentioned is very good and profound. I would like to share my views from the following aspects: Firstly, I was involved in this field quite early on. I have been involved since the first official research was conducted in...

Dr. Chen Weijie Chairman of Lishan Biotech Firstly, we warmly welcome Dr. Du to Lishan. The comprehensive strategic cooperation between Lishan and Eglin is a new starting point, and we look forward to more achievements in the future. Firstly, I would like to ask Dr. Du how you view the live biopharmaceutical LBP industry? We have found that there are some large pharmaceutical companies in the United States, such as Nestle investing in Seres and Pfizer investing in Vedanta, and it seems that this industry is slowly starting to heat up. But I also heard some different voices, such as that its safety is acceptable, but its effectiveness and mechanism are very complex. What is your opinion on the live microbial medicine industry?   Dr. Du Tao Chairman of Eglin Pharmaceuticals Okay, I am Du Tao, the chairman of Eglin Pharmaceuticals in Shenzhen ...